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analyzed for 365 days after and before the accrual period. RESULTS: On a total of 
2,962,498 subjects observed, 594 patients were hospitalized for melanoma (53.4% 
males) during 2009 (prevalence rate: 20.0 per 100,000). Among them, 43% had at 
least one chronic comorbidity, hypertension is the most common (14.6%) 
followed by combination of dyslipidemia and hypertension (3.0%). Therapy for 
melanoma is made both in and outside the hospital. Interferon alfa-2b was the 
most prescribed treatment outside the hospital with an average cost of €110, 
followed by Temozolomide (€40.7) and Erythropoietin (€39.6). During one-year of 
follow-up, 13% of patients was hospitalized for chemotherapy with an average 
cost of €7398. This amount covers also drug treatment cost during 
hospitalization. The average yearly cost/patient for population with melanoma 
was €4777 (hospitalizations: 70.8%, drugs: 14.4%, diagnostic examinations: 
14.8%), with an higher cost for the subgroup of patient already in treatment the 
previous year before the accrual period (€6156 vs €4361). If we consider the 
subgroup of patient with metastatic melanoma (N=176), the overall cost rises at 
€15,984, most of it (60%) due to drug costs for specific therapy of melanoma and 
chemotherapy. Surprisingly methotrexate and cyclophosphamide appear in the 
top five list of prescribed drugs. CONCLUSIONS: This study shows high cost of 
patients with melanoma and how real world practice therapy, especially for 
metastatic melanoma, seems to be far from the guidelines recommendation. 
This suggests to create a regional network to correctly redirect therapeutic 
choices.  
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OBJECTIVES: Diabetes mellitus (DM) is recognised as a major health problem. Its 
chronic nature and complications make it a costly disease. The aim of this study 
is two-fold: (1) to describe the methods used in the identified cost-of-illness (COI) 
studies of DM and (2) to summarise their study findings regarding the economic 
impact of DM. METHODS: This is a systematic review of MEDLINE and Scopus 
journal articles reporting the cost of type-1 and/or type-2 DM that were 
published in English from 2007 to 2011. Costs reported in the included studies 
were converted to US dollars for comparison purposes. RESULTS: The systematic 
search yielded 30 articles that met the predetermined criteria. The studies varied 
considerably in their study design, perspective and included cost categories. 
Estimates for the total annual costs of DM ranged from US$141.6 million to 
US$174 billion; direct costs ranged from US$150 to US$14,060 per patient per year 
(pppy) whereas indirect costs ranged from US$39.6 to US$7,164 pppy. Inpatient 
cost was the major contributor to direct cost in half of the studies that included 
inpatient costs, physician services and medications. In addition, patients with 
DM consumed significantly more health care resources and incurred higher 
health care costs than patients without DM. CONCLUSIONS: There is a 
considerable economic burden associated with DM, not only on the health care 
system, but also on the individual and society as a whole. Future research should 
focus on improving methods of estimating costs, enhancing the interpretation of 
study findings and facilitating comparisons between studies.  
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OBJECTIVES: To evaluate the cost of Pulmonary Arterial Hypertension (PAH) to 
health services in Mexico based on epidemiological trends, to project this 
estimate to 2012. METHODS: Retrospective medical chart review using data from 
the NIC. Clinical and resource utilization data for all patients admitted to the NIC 
with PAH between January 1, 2009 and 2011 were collected and the mean 
treatment costs per person were calculated by assigning appropriate unit cost 
data to all resource use. A prevalence based approach was used to estimate the 
economic burden of PAH. Contemporary data were obtained from 
epidemiological studies, government datasets, and other sources to estimate 
prevalence. National costs (US dollar 2012) of treatment for PAH were estimated 
by extrapolation of mean cost estimate per person to national incidence data for 
PAH. Because of uncertainties surrounding some of our estimates such as 
prevalence, one way sensitivity analyses were undertaken. RESULTS: A total of 
113 PAH patients were identified and their demographic and clinical 
characteristics, patterns of care were examined. The mean age was 38 years, and 
83% were female. The average per patient annual cost was $ 10,869 without 
specific treatment (min $ 137; max $155,928). The annual cost for the treatment 
of a single PAH patient per year with specific therapy (Bosentan) was calculated 
in $31.433. Aggregate national health care expenditures for treatment of PAH 
were USD 46.6 million In multivariate analysis, length of hospital stay, stay in 
ICU, were all significant independent predictors of treatment CONCLUSIONS: 
Treatment costs of PAH in Mexico are substantial and primarily driven by the 
intensity of hospital treatment. With the expected increase in the incidence of 
PAH in Mexico over the coming decades, these results emphasize the need for 
effective preventive and acute medical care.  
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OBJECTIVES: The current study aimed to examine direct medical cost and 
humanistic outcome of diastolic heart failure (DHF) management in Hong Kong. 
Whether the presence of comorbidities, including hypertension, diabetes and 
renal impairment, affect the cost and humanistic outcome was also evaluated. 
METHODS: Retrospective, non-randomized study design was adopted. Subjects 
were recruited from the Heart Failure Registry of the Prince of Wales Hospital in 
Hong Kong between 2006 and 2008 and completion of the Minnesota Living with 
Heart Failure Questionnaire (MLHFQ) at 3 designated time pints to be eligible. 
Patients with significant valvular disorder were excluded. One year medical 
records since admission were reviewed. Heart failure related admissions, clinic 
visits, cardiovascular drugs, laboratory and diagnostic tests were recorded. The 
costs and MLHFQ scores in patients with or without hypertension, diabetes, and 
renal impairment were compared. Non-parametric Wilcoxon Signed Rank and 
Mann-Whitney tests were used. A p-value < 0.05 was considered statistically 
significant. RESULTS: A total of 73 DHF patients were included. The mean 1-year 
direct medical cost was USD 20,098 (1 USD = 7.75 HKD), with in-patient care cost 
contributing to the largest proportion (72.2%) of the total cost. Patients with 
diabetes or renal impairment were associated with a higher cost of DHF 
management. Significant difference was found in the renal impairment group 
(median cost: USD 24,763 versus USD 12,789 in no impairment group, p=0.023). 
The mean MLHFQ scores of the subjects improved significantly from baseline 
30.81±13.89 to 12 months 15.84 ±11.32 (p<0.0005). CONCLUSIONS: The cost of 
management of DHF was shown to be enormous and further increased in the 
presence of comorbidities. With the aging population in Hong Kong, the 
incidence of DHF is expected to increase progressively. Further studies are 
demanded to guide more optimal medical resource allocation for DHF 
management.  
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OBJECTIVES: Prostate cancer is the second leading cancer diagnosed among 
men. In Spain the incidence of prostate cancer was 100.4 cases per 100,000 
males. Advanced prostate cancer is cancer that has spread outside of the 
prostate capsule and may involve other parts of the body, most commonly to the 
lymph nodes and bones . The aim of this study was to estimate the lifetime costs 
of a cohort of advanced prostate cancer patients diagnosed in Spain in 2012. 
METHODS: An economic model was developed in EXCEL incorporating Spanish 
incidence, mortality and cost data supplemented with data from the 
international literature. Progression from Stage III to Stage IV was permitted. 
Costs were discounted. Lifetime costs were presented on an individual basis and 
for the entire cohort of newly diagnosed Stage III and Stage IV prostate cancer 
patients. RESULTS: Lifetime costs for advanced prostate cancer were 
approximately 23,032 € per patient. Using the projected incident cases for 2012, 
the total cost for the incident cohort of patients in 2012 would amount to 172 
million euros. These results were more sensitive to changes in the ongoing costs 
(post initial 12 months) of Stage III prostate cancer, the rate of progression from 
Stage III to Stage IV and the discount rate applied to costs. CONCLUSIONS: This 
study provides an estimate of the lifetime costs of advanced prostate cancer in 
Spain and a framework for further research. Until improved long-term 
prospective or observational data do become available the current results 
indicate that the burden of advanced prostate cancer is substantial and will 
increase due to an increasing number of new cases and reductions in mortality. 
Any treatments that could potentially reduce the economic burden of the disease 
should be of interest to health care decision makers given the context of limited 
resources in Europe.  
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OBJECTIVES: To evaluate the health care cost of diabetes with co-morbidities by 
using cost of illness analysis. METHODS: A prospective observational study was 
conducted for a period of six months at Rohini super specialty hospital, AP, 
India. The patients were identified during ward rounds and by regular case 
record reviews during study period. The enrolled patients were followed from 
the day of admission till the day of discharge and the relevant study data 
including total direct costs which include direct medical costs, cost of laboratory 
investigations, cost of consultation, cost of hospitalization, direct nonmedical 
cost includes the transportation cost to hospital and indirect costs which include 
days lost from work or productivity, was documented in case record form. 
RESULTS: A total of 150 patients were enrolled during the study period. The 
average cost per diabetic patient without complications was Rs. 1623 this 
includes the average total direct medical cost was Rs.1483 (91.37%), the average 
direct non medical cost was Rs. 20 (1.23%) and the average total indirect cost was 
Rs. 120 (7.4%) compared to for those with diabetes complications, Rs. 7706 for 
macrovascular complications, Rs. 4907 for microvascular complications and Rs. 
2810 others infections. The cost for the treat diabetes with co morbidities was 
found to be Rs. 17046, the average total direct medical cost was Rs. 15738 
(92.41%), the average direct non medical cost was Rs. 204 (1.12%) and the average 
total indirect cost was Rs. 1104 (6.47%). CONCLUSIONS: Our study results 
